Market News
Stay updated with the latest market trends, earnings, and economic indicators.
Healthcare, engineering and specialty chemicals remain key market themes: Mayuresh Joshi
Mayuresh Joshi, Director Research at Marketsmith India, believes execution will remain key for companies like Suzlon, while healthcare, engineering and select speciality chemical names continue to offer strong growth opportunities. He also sees India-focused engineering and capital goods companies remaining resilient despite global uncertainties. Joshi says investors should stay selective in IT, remains positive on Navin Fluorine, and is closely tracking niche AI-linked opportunities emerging in smaller tech firms.
Sakar Healthcare partners with Zydus Lifesciences for GCC Markets
Sakar Healthcare has partnered with Zydus Lifesciences to supply oncology products in GCC countries and other emerging markets. This marks the company's 40th global agreement in the anti-cancer segment. Sakar Healthcare is expanding its international oncology business and strengthening its presence in emerging markets. The company is also progressing with regulatory filings and approvals in highly regulated markets.
Anupam Rasayan enters formulations business with ₹1,369 cr Bliss GVS Pharma acquisition
Anupam Rasayan will acquire up to 74.2% stake in Bliss GVS Pharma, strengthening its presence across the pharmaceutical value chain and expanding its reach in regulated global markets.
Venus Remedies gets Saudi FDA approval for speciality oncology therapy
Venus Remedies Limited has secured its first global marketing authorization for its specialty oncology therapy, Plerixafor, from the Saudi Food and Drug Authority (SFDA). This hematopoietic stem cell mobilizer is crucial for patients undergoing stem cell transplantation for multiple myeloma and non-Hodgkin lymphoma.
Sun Pharma sees steady FY27 growth, progresses $11.75 bn Organon integration deal
Sun Pharma anticipates strong growth in the coming years. The company expects a high single-digit increase in its overall sales by FY2027. Significant progress is being made on the acquisition of Organon, with completion targeted for the last quarter of FY2027. This strategic move is set to enhance Sun Pharma's global presence and product portfolio across key therapeutic areas.
Is Ebola The Next Big Pandemic? Ex-CDC Chief Rings Alarm Even As WHO Sees Low Global Risk
Health officials in the DRC and Uganda have recorded at least 139 deaths from over 600 probable cases of the current Ebola outbreak.
India Inc's foreign investments more than double in April
Indian companies significantly boosted overseas investments in April. Direct investments surged to $3.37 billion, more than doubling from March. Equity investments led this growth. Coforge was a major investor, with other companies like Lupin and Wingify Software also making substantial commitments. These investments spanned various sectors and regions, indicating active global expansion by Indian businesses.
India Inc's foreign investments more than double in April
Indian companies significantly boosted overseas investments in April. Direct investments surged to $3.37 billion, more than doubling from March. Equity investments led this growth. Coforge was a major investor, with other companies like Lupin and Wingify Software also making substantial commitments. These investments spanned various sectors and regions, indicating active global expansion by Indian businesses.
Sun Pharma Q4 Preview: Can Unloxcyt and speciality drugs help pharma major deliver another strong quarter?
Sun Pharma is expected to post double-digit revenue growth in Q4FY26, driven by strong performance across speciality drugs, domestic formulations, and emerging markets. Brokerages highlight US portfolio strength, new launches like Unloxcyt, and a steady margin outlook despite higher R&D spending, with EBITDA growth supported by diversified global business momentum outlook
INR recovers from historic lows as oil pulls back; RBI announces $5 billion US Dollar/INR swap auction to defend rupee
The Indian rupee recovered well in opening trades on Thursday as global investors noted a slight pullback in crude oil prices over the recent comments on a potential final stage of the US-Iran conflict. INR opened at Rs 96.25 per dollar and hit a high of 96.05 so far during the day. Yesterday, the counter ended near the next critical level of 96.86, a new historic low. Meanwhile, in a major structural intervention to stabilise domestic financial markets, the Reserve Bank of India (RBI) has announced a $5 billion USD/INR buy-sell swap auction. Scheduled to take place next week on Tuesday, May 26, the central banks move is specifically engineered to inject durable, long-term Rupee liquidity into the commercial banking system. The Indian Rupee has faced persistent downward pressure, depreciating significantly against the American greenback in recent weeks due to ongoing global macroeconomic uncertainties and shifting foreign capital flows. By deploying this specialised monetary tool, ...
Metro Brands, Jubilant FoodWorks fairly priced; Apollo Hospitals a strong compounder: Dipan Mehta
Dipan Mehta, Director of Elixir Equities says Metro Brands and Jubilant FoodWorks look fairly valued at 65-70x trailing earnings — better to wait for a dip. Apollo Hospitals impressed with record revenues and strong operating leverage. On large global IPOs like SpaceX, he warns that private equity has already captured the big gains, leaving public market investors to buy in at peak valuations. Disclaimer: The views and investment tips expressed by investment experts on CNBCTV18.com are their own and not that of the website or its management. CNBCTV18.com advises users to check with certified experts before taking any investment decisions.
No Ebola case in India yet, centre reviews preparedness after WHO declares global health emergency
India's Health Ministry held a high-level meeting to assess preparedness for Ebola Virus Disease following a WHO declaration. Officials confirmed no cases in India and urged calm, emphasizing the nation's vigilance and readiness. States have been directed to ensure readiness at all levels, with SOPs circulated for screening, quarantine, and case management.